Pharma & Biotech Solutions
Clear outcomes for your clinical trials.
Neurodegenerative diseases exhibit significant heterogeneity, making clinical trials inherently challenging. Patients often present with diverse symptoms and varying rates of disease progression. This variability highlights the need for a reliable approach for precise patient stratification and robust tracking of brain changes over time, supporting impactful clinical trials.
Discover the impact
Detecting microstructural changes before they lead to subsequent macrostructural alterations offers early insights into disease progression. Our CDM technology analyses the microstructure of the cortical grey matter to provide a more sensitive assessment of drug treatment impact.
Track AD
Monitor disease progression and drug efficacy
Throughout the clinical trial, advanced metrics capture insights to grey matter quality changes. Results can be summarised over lobes, the whole brain, or tailored to specific brain regions, meta-regions or disease signatures, offering flexible insights to support drug impact and disease progression tracking.
Find the right patient
Our Cortical Disarray Measurement (CDM) technology analyses the microstructure of disease-specific brain regions. Innovative diffusion MRI-based biomarkers provide a precise assessments of pathological stages and predict disease progression for up to 3 years, elevating patient stratification for clinical trials.
Select AD
Optimise patient selection for clinical trials
Grey matter analysis, integrated with clinical data and patient demographics, ensures that each patient is at the right stage for trial participation. Predictive insights are provided on the likelihood of disease progression, facilitating optimal patient selection.
- Disease stage classification
- Prediction of patient disease progression
- Dropout rate and cost reduction
Relevant Media & Publications
Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study.
|
Clinical utility of diffusion MRI-derived measures of cortical microstructure in a real-world memory clinic setting.
|
